Allure Imports sold unapproved Silver Soul and Vitality C60 products claimed to treat COVID-19.
What happened
FDA and FTC reviewed Allure Imports’ websites and social media on 02/25/21 and 03/31/21 and found Silver Soul Immune Support, Silver Soul Body Spray, and Vitality C60 offered for sale in the United States with claims to mitigate, prevent, treat, diagnose, or cure COVID-19. FDA said the products are unapproved new drugs and misbranded (labeled or promoted in violation of drug law), and that Vitality C60 is also an unapproved animal drug for COVID-19 use in animals. The letter cites website claims about colloidal silver and C60 for coronavirus and for pets.
What FDA found
The company offered Silver Soul Immune Support, Silver Soul Body Spray, and Vitality C60 as COVID-19 treatments without FDA approval as new drugs.
Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)FDA cited the products as misbranded (labeled or promoted in violation of drug law) because of the COVID-19 claims.
Section 502 of the FD&C Act, 21 U.S.C. § 352Vitality C60 was promoted to mitigate, treat, or prevent COVID-19 in animals, making it a drug for animals.
Section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. § 321(g)(1)(B)Vitality C60 had no approved or conditionally approved animal drug application or index listing, so FDA considered it unsafe and adulterated.
Sections 512(a) and 501(a)(5) of the FD&C Act, 21 U.S.C. §§ 360b(a), 351(a)(5)The company introduced or delivered the products into interstate commerce despite the violations.
Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)The company advertised that the products could prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. 41 et seq.
What FDA wants
FDA asks the company to take immediate action to stop selling the unapproved and unauthorized COVID-19 products and to email COVID-19-Task-Force-CDER@fda.hhs.gov within 48 hours describing the specific steps taken and how it will prevent recurrence. If it cannot complete action within 48 hours, it must state the reason for delay and the time within which it will do so.
Who should pay attention
- online supplement sellers making disease treatment claims
- retailers and marketplaces listing COVID-19-related supplements
- pet product sellers making immune or antiviral claims
This is a summary. Read the original letter on fda.gov.